Izilendustat
Izilendustat is a potent inhibitor of prolyl hydroxylase which can stabilize hypoxia inducible factor- 1 alpha (HIF- lα) and hypoxia inducible factor-2 (HIF-2) . Izilendustat has the potential for researching diseases that relate to the body’s inmmune response like colitis and other inflammatory bowel diseases (extracted from patent WO2011057115A1 and WO2011057121A1) [1][1].
Product Specifications
CAS Number
1303512-02-8
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
HIF/HIF Prolyl-Hydroxylase
Type
Reference compound
Related Pathways
Metabolic Enzyme/Protease
Applications
COVID-19-immunoregulation
Field of Research
Inflammation/Immunology; Cardiovascular Disease
Assay Protocol
https://www.medchemexpress.com/izilendustat.html
Purity
99.20
Solubility
DMSO : 25 mg/mL (ultrasonic; warming; heat to 60°C)
Smiles
O=C(N1CCN(CC(C=CN2CC3=CC=C(Cl)C=C3)=C(O)C2=O)CC1)OC(C)(C)C
Molecular Formula
C22H28ClN3O4
Molecular Weight
433.94
Precautions
H302, H315, H319, H335
References & Citations
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
Nuclear Transcription Factor Y Subunit Alpha (NFYA) Antibody
